The case for replacing live oral polio vaccine with inactivated vaccine in the Americas.
作者信息
Alfaro-Murillo Jorge A, Ávila-Agüero Marí L, Fitzpatrick Meagan C, Crystal Caroline J, Falleiros-Arlant Luiza-Helena, Galvani Alison P
机构信息
Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, USA.
Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, USA; Paediatric Infectious Diseases Department, Hospital Nacional de Niños "Dr Carlos Sáenz Herrera", San José, Costa Rica.
出版信息
Lancet. 2020 Apr 4;395(10230):1163-1166. doi: 10.1016/S0140-6736(20)30213-0.
Abstract
摘要
相似文献
1
The case for replacing live oral polio vaccine with inactivated vaccine in the Americas.美洲地区用灭活疫苗替代口服脊髓灰质炎减毒活疫苗的理由。
Lancet. 2020 Apr 4;395(10230):1163-1166. doi: 10.1016/S0140-6736(20)30213-0.
2
Decision analysis in planning for a polio outbreak in the United States.美国脊髓灰质炎疫情应对规划中的决策分析
Pediatrics. 2006 Aug;118(2):611-8. doi: 10.1542/peds.2005-2358.
3
Circulating vaccine derived poliovirus and the polio eradication endgame.循环疫苗衍生脊髓灰质炎病毒与脊髓灰质炎根除的最后阶段
Pan Afr Med J. 2012;12:109. Epub 2012 Aug 20.
4
Effect of Inactivated Poliovirus Vaccine Campaigns, Pakistan, 2014-2017.2014-2017 年巴基斯坦脊髓灰质炎灭活疫苗运动的效果。
Emerg Infect Dis. 2018 Nov;24(11):2113-2115. doi: 10.3201/eid2411.180050. Epub 2018 Nov 17.
5
World wide experience with inactivated poliovirus vaccine.全球使用灭活脊髓灰质炎疫苗的经验。
Vaccine. 2008 Sep 15;26(39):4978-83. doi: 10.1016/j.vaccine.2008.07.026. Epub 2008 Aug 3.
6
Oral polio vaccines and their role in polio eradication in India.口服脊髓灰质炎疫苗及其在印度根除脊髓灰质炎中的作用。
Expert Rev Vaccines. 2009 Jan;8(1):35-41. doi: 10.1586/14760584.8.1.35.
7
Role of injectable and oral polio vaccines in polio eradication.注射用和口服脊髓灰质炎疫苗在根除脊髓灰质炎中的作用。
Expert Rev Vaccines. 2009 Jan;8(1):5-8. doi: 10.1586/14760584.8.1.5.
8
Protocol versus practice of supplementary immunization activity (SIA) for polio eradication in Pakistan.巴基斯坦根除脊髓灰质炎补充免疫活动（SIA）的方案与实践
Vaccine. 2015 Jun 26;33(29):3270. doi: 10.1016/j.vaccine.2015.01.067. Epub 2015 Feb 7.
9
Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988-1995.美洲野生脊髓灰质炎病毒的根除：1988 - 1995年急性弛缓性麻痹监测
J Infect Dis. 1997 Feb;175 Suppl 1:S37-42. doi: 10.1093/infdis/175.supplement_1.s37.
10
Current issues in evaluating the efficacy of oral poliovirus vaccine and inactivated poliovirus vaccine immunization.评估口服脊髓灰质炎疫苗和灭活脊髓灰质炎疫苗免疫效果的当前问题。
Pediatr Infect Dis J. 1991 Dec;10(12):979-81. doi: 10.1097/00006454-199112000-00032.
引用本文的文献
1
Individual and community level maternal factors for zero-dose children in Ethiopia using mini-EDHS 2019: a mixed effects model.使用2019年埃塞俄比亚微型人口与健康调查分析零剂量疫苗儿童的个体和社区层面的孕产妇因素：混合效应模型
BMJ Open. 2025 Jan 7;15(1):e085235. doi: 10.1136/bmjopen-2024-085235.
2
Polio Epidemiology: Strategies and Challenges for Polio Eradication Post the COVID-19 Pandemic.脊髓灰质炎流行病学：新冠疫情后根除脊髓灰质炎的策略与挑战
Vaccines (Basel). 2024 Nov 26;12(12):1323. doi: 10.3390/vaccines12121323.
3
Geospatial mapping to assess the distribution and determinants of zero dose vaccination status hot spots among children in Ethiopia using EDHS 2019: Spatial and geographical weighted regression.利用2019年埃塞俄比亚人口与健康调查进行地理空间映射，以评估埃塞俄比亚儿童中零剂量疫苗接种状况热点地区的分布及决定因素：空间和地理加权回归
PLoS One. 2024 Dec 31;19(12):e0312610. doi: 10.1371/journal.pone.0312610. eCollection 2024.
4
Non-uptake of dual protective polio vaccine and its determinants among children in Ethiopia using Ethiopian Demographic Health Survey 2019: a mixed-effect model.利用2019年埃塞俄比亚人口与健康调查分析埃塞俄比亚儿童对双价脊髓灰质炎灭活疫苗的接种情况及其影响因素：混合效应模型
BMJ Open. 2024 Aug 31;14(8):e083648. doi: 10.1136/bmjopen-2023-083648.
5
Mapping disparities in viral infection rates using highly multiplexed serology.利用高度多重化血清学技术绘制病毒感染率的差异图谱。
mSphere. 2024 Sep 25;9(9):e0012724. doi: 10.1128/msphere.00127-24. Epub 2024 Aug 20.
6
Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges-A Narrative Review.疫苗的药物警戒：重要性、主要方面、前景与挑战——一篇叙述性综述
Pharmaceuticals (Basel). 2024 Jun 19;17(6):807. doi: 10.3390/ph17060807.
7
Inactivated Poliovirus Vaccine Booster Reduces the Likelihood of COVID-19 Outcomes in Individuals Primed with Oral Poliovirus Vaccination.灭活脊髓灰质炎病毒疫苗加强针可降低口服脊髓灰质炎疫苗初免个体出现新冠病毒感染相关结果的可能性。
Vaccines (Basel). 2024 Feb 20;12(3):219. doi: 10.3390/vaccines12030219.
8
Is it time to switch to a formulation other than the live attenuated poliovirus vaccine to prevent poliomyelitis?是否到了改用其他减毒活疫苗而非口服脊髓灰质炎减毒活疫苗来预防脊髓灰质炎的时候了？
Front Public Health. 2024 Jan 8;11:1284337. doi: 10.3389/fpubh.2023.1284337. eCollection 2023.
9
Oral and Inactivated Polio Vaccine Coverage and Determinants of Coverage Inequality Among the Most At-Risk Populations in Ethiopia.埃塞俄比亚高危人群口服和灭活脊髓灰质炎疫苗接种率及覆盖率不平等的决定因素。
Am J Trop Med Hyg. 2023 Sep 25;109(5):1148-1156. doi: 10.4269/ajtmh.23-0319. Print 2023 Nov 1.
10
Immune persistence of an inactivated poliovirus vaccine derived from the Sabin strain: a 10-year follow-up of a phase 3 study.源自萨宾株的灭活脊髓灰质炎疫苗的免疫持久性：一项3期研究的10年随访
EClinicalMedicine. 2023 Sep 14;64:102151. doi: 10.1016/j.eclinm.2023.102151. eCollection 2023 Oct.
本文引用的文献
1
Circulating vaccine-derived poliovirus: a menace to the end game of polio eradication.循环疫苗衍生脊髓灰质炎病毒：消灭脊髓灰质炎行动的威胁。
Global Health. 2020 Jul 16;16(1):63. doi: 10.1186/s12992-020-00594-z.
2
Immunogenicity of Intramuscular Fractional Dose of Inactivated Poliovirus Vaccine.肌内注射小剂量脊髓灰质炎灭活疫苗的免疫原性。
J Infect Dis. 2020 Mar 2;221(6):895-901. doi: 10.1093/infdis/jiz323.
3
The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.两种新型口服减毒单价（血清型 2）脊灰病毒疫苗在健康成年人中的安全性和免疫原性：一项双盲、单中心 1 期研究。
Lancet. 2019 Jul 13;394(10193):148-158. doi: 10.1016/S0140-6736(19)31279-6. Epub 2019 Jun 4.
4
Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry.原发性免疫缺陷病个体中脊髓灰质炎病毒的长期排泄：世界卫生组织登记处分析
Front Immunol. 2017 Sep 25;8:1103. doi: 10.3389/fimmu.2017.01103. eCollection 2017.
5
Boosting Immune Responses Following Fractional-Dose Inactivated Poliovirus Vaccine: A Randomized, Controlled Trial.小剂量灭活脊髓灰质炎疫苗接种后增强免疫反应：一项随机对照试验。
J Infect Dis. 2017 Jan 15;215(2):175-182. doi: 10.1093/infdis/jiw492.
6
Environmental Surveillance of Polioviruses in Rio de Janeiro, Brazil, in Support to the Activities of Global Polio Eradication Initiative.巴西里约热内卢脊髓灰质炎病毒的环境监测，以支持全球根除脊髓灰质炎行动的各项活动。
Food Environ Virol. 2016 Mar;8(1):27-33. doi: 10.1007/s12560-015-9221-5. Epub 2015 Nov 4.
7
Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.免疫缺陷相关的长期疫苗衍生脊髓灰质炎病毒排泄者患病率建模及抗病毒药物的潜在益处
BMC Infect Dis. 2015 Sep 17;15:379. doi: 10.1186/s12879-015-1115-5.
8
Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.在智利婴儿中单独使用或与二价口服脊髓灰质炎疫苗序贯使用灭活脊髓灰质炎病毒疫苗：一项随机、对照、开放性标签、四期、非劣效性研究。
Lancet Infect Dis. 2015 Nov;15(11):1273-82. doi: 10.1016/S1473-3099(15)00219-4. Epub 2015 Aug 26.
9
Polio vaccination: past, present and future.脊髓灰质炎疫苗接种：过去、现在与未来。
Future Microbiol. 2015;10(5):791-808. doi: 10.2217/fmb.15.19. Epub 2015 Mar 31.
10
Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden.疫苗相关麻痹型脊髓灰质炎：流行病学综述及全球负担估计
J Infect Dis. 2014 Nov 1;210 Suppl 1(Suppl 1):S380-9. doi: 10.1093/infdis/jiu184.
Zotero 插件